Why Geron Stock Is Jumping Today
Shares of the clinical-stage biotech Geron (NASDAQ: GERN) are up by 10.4% as of 9:46 a.m EDT. The spark?
Geron's shares are jumping this morning on the news that the Food and Drug Administration granted the company's sole drug candidate, imetelstat, Fast Track designation as a potential treatment for patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment or relapsed/refractory MF.
Image Source: Getty Images.
Source Fool.com
